Implications of Topoisomerase (TOP1 and TOP2α) Expression in Patients With Breast Cancer

被引:12
|
作者
Ogino, Misato [1 ,2 ,3 ]
Fujii, Takaaki [1 ,2 ]
Nakazawa, Yuko [1 ,2 ]
Higuchi, Toru [4 ]
Koibuchi, Yukio [3 ]
Oyama, Tetsunari [5 ]
Horiguchi, Jun [6 ]
Shirabe, Ken [2 ]
机构
[1] Gunma Univ, Grad Sch Med, Div Breast & Endocrine Surg, Gunma, Japan
[2] Gunma Univ, Grad Sch Med, Dept Gen Surg Sci, 3-39-22 Showa Machi, Maebashi, Gumma 3718511, Japan
[3] Natl Hosp Org, Takasaki Gen Med Ctr, Dept Breast & Endocrine Surg, Gunma, Japan
[4] Japanese Red Cross Saitama Hosp, Dept Breast Surg, Saitama, Japan
[5] Gunma Univ, Dept Diagnost Pathol, Gunma, Japan
[6] Int Univ Hlth & Welf, Dept Breast Surg, Chiba, Japan
来源
IN VIVO | 2020年 / 34卷 / 06期
关键词
Topoisomerase I; topoisomerase II alpha; breast cancer; CARCINOMA; CARCINOGENESIS; AMPLIFICATION;
D O I
10.21873/invivo.12188
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background/Aim: We evaluated the usefulness of topoisomerases (TOPs) expression as prognostic predictors in breast cancer. Patients and Methods: We retrospectively investigated sixty cases with primary breast cancer. We evaluated the tumor and non-tumor mRNA levels of TOP1 and TOP2 alpha using quantitative reverse-transcription polymerase chain reaction. TOP1/TOP2 alpha positivity was defined as the ratio of the mRNA expression of cancer/normal tissue of >1 for both TOP1 and TOP2 alpha. Results: TOP1 and TOP2 alpha were markedly overexpressed in breast cancer tissues compared to normal breast tissues. Of the 60 cases, 46 (76.7%) were positive for TOP1/TOP2 alpha. The relapse-free survival was relatively shorter for patients with positive TOP1/TOP2 alpha. There was no recurrent disease among the 14 patients who were negative for TOP1/TOP2 alpha, whereas four of the 46 TOP1/TOP2 alpha-positive patients had disease recurrence. Conclusion: Negative TOP1 or TOP2 alpha expression may be useful for predicting better prognoses in breast cancer patients.
引用
收藏
页码:3483 / 3487
页数:5
相关论文
共 50 条
  • [1] Top1 and Top2 promote replication fork arrest at a programmed pause site
    Larcher, Melanie V.
    Pasero, Philippe
    GENES & DEVELOPMENT, 2020, 34 (1-2) : 1 - 3
  • [2] UV-SENSITIVITY OF DOUBLE TOP1 TOP2 MUTANTS IN YEAST, SACCHAROMYCES-CEREVISIAE
    MACHIDA, I
    SAEKI, T
    JOURNAL OF RADIATION RESEARCH, 1987, 28 (01) : 27 - 27
  • [3] The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2
    Marzi, Laetitia
    Sun, Yilun
    Huang, Shar-yin N.
    James, Amy
    Difilippantonio, Simone
    Pommier, Yves
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (08) : 1589 - 1597
  • [4] Predictive value of topoisomerase 1 by immunohistochemistry (TOP1 IHC) in patients with metastatic breast cancer receiving irinotecan-based therapy.
    Robert, Nicholas J.
    Anthony, Stephen Patrick
    Arguello, David
    Jameson, Gayle S.
    Northfelt, Donald W.
    Jahanzeb, Mohammad
    Petricoin, Emanuel
    Pierobon, Mariaelena
    Dunetz, Bryant
    Liotta, Lance A.
    Loesch, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] The Arabidopsis oligopeptidases TOP1 and TOP2 are salicylic acid targets that modulate SA-mediated signaling and the immune response
    Moreau, Magali
    Westlake, Timothy
    Zampogna, Giulio
    Popescu, George
    Tian, Miaoying
    Noutsos, Christos
    Popescu, Sorina
    PLANT JOURNAL, 2013, 76 (04): : 603 - 614
  • [6] Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis
    Romer, Maria Unni
    Nygard, Sune Boris
    Christensen, Ib Jarle
    Nielsen, Signe Lykke
    Nielsen, Kirsten Vang
    Muller, Sven
    Smith, David Hersi
    Vainer, Ben
    Nielsen, Hans Jorgen
    Brunner, Nils
    MOLECULAR ONCOLOGY, 2013, 7 (01) : 101 - 111
  • [7] The essential DNA topoisomerase, Top2, is required for normal nuclear morphology
    Meseroll, R. A.
    Cohen-Fix, O.
    MOLECULAR BIOLOGY OF THE CELL, 2015, 26
  • [8] Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations
    Atwal, Mandeep
    Swan, Rebecca L.
    Rowe, Chloe
    Lee, Ka C.
    Lee, David C.
    Armstrong, Lyle
    Cowell, Ian G.
    Austin, Caroline A.
    MOLECULAR PHARMACOLOGY, 2019, 96 (04) : 475 - 484
  • [9] TOP1 mutations mediate cross resistance to ADCs in metastatic breast cancer
    Abelman, Rachel Occhiogrosso
    Barnes, Haley
    Medford, Arielle J.
    Putur, Annika
    Wu, Bogang
    Weipert, Caroline
    Fell, Geoffrey
    Spring, Laura M.
    Wander, Seth A.
    Moy, Beverly
    Varkaris, Andreas
    Juric, Dejan
    Ellisen, Leif
    Corcoran, Ryan
    Bardia, Aditya
    CANCER RESEARCH, 2024, 84 (06)
  • [10] The NEDD8 inhibitor pevonedistat blocks the repair of topoisomerase I (TOP1)-induced replication damage and synergizes with TOP1 inhibitors.
    Sun, Yilun
    Baechler, Andrea
    Factor, Valentina
    Okamoto, Kanako
    Pommier, Yves
    CANCER RESEARCH, 2021, 81 (13)